Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Malignancy risk from genetically modified immune effector cells, p53 immunohistochemistry as a new tool in AML, and phenotypic escape from CD19-directed immunotherapies.

    Malignancy risk from genetically modified immune effector cells, p53 immunohistochemistry as a new tool in AML, and phenotypic escape from CD19-direct…

    FromBlood Podcast

    Start listeningView podcast show

    Malignancy risk from genetically modified immune effector cells, p53 immunohistochemistry as a new tool in AML, and phenotypic escape from CD19-direct…

    FromBlood Podcast

    ratings:
    Length:
    22 minutes
    Released:
    Jul 7, 2022
    Format:
    Podcast episode

    Description

    Today we’ll learn more about the risk of subsequent malignancies in patients treated with genetically modified immune effector cells, discuss how p53 immunohistochemistry can be a global readout for TP53 alterations in AML, and uncover the role of CD19-negative CD22-positive B-cell progenitors in immune escape from CD19-directed therapies.
    Released:
    Jul 7, 2022
    Format:
    Podcast episode

    Titles in the series (100)

    The Blood Podcast summarizes content recently published in Blood the most cited peer-reviewed publication in the field of hematology.